Alzheimer’s Drug Development Comparable To Cancer 50 Years Ago – Targacept CEO
This article was originally published in Pharmaceutical Approvals Monthly
Developing drugs to effectively treat Alzheimer's disease has been stymied by a failure to understand underlying causes of the disease, according to industry panelists at the BioInvestor Forum in San Francisco
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class